Investigational drug · Phase 2
CPX101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Overweight and Obesity.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "CPX101"
First trial start
2024
Aug 13, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CPX101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Overweight and Obesity
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "CPX101" as an intervention, largest first.
- Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes MellitusPivotal-lookingCompleted
Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.Industry
NCT06532578 · 240 participants · Start Aug 13, 2024 · Primary completion Dec 15, 2025
Drug: CPX101 or placebo 120mg Q2W; CPX101 or placebo 160mg Q4W and 5 more · For: Overweight and Obesity
Sites: Chatswood, Australia
- Safety, Tolerability, and Pharmacokinetics of a Single or Multiple Ascending Doses of CPX101Completed
Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.Industry
NCT06545162 · 72 participants · Start Dec 4, 2024 · Primary completion Dec 30, 2025
Drug: CPX101 or placebo 80mg single dose; CPX101 or placebo 120mg single dose and 5 more · For: Overweight and Obesity
Sites: Beijing, China · 3 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Activity of the cytosolic isozyme of thymidine kinase in human primary lung tumors with reference to malignancy.
Yusa T, Yamaguchi Y, Ohwada H, et al. · Cancer Res 1988
Also in development for Overweight and Obesity
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
- MazdutideLY3305677Phase 35 trials
Eli Lilly · Type 2 Diabetes, Obesity, Overweight
- HDM1002Phase 34 trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight and Obesity
- DA-302168SPhase 33 trials
Chendu DIAO Pharmaceutical Group CO., LTD. · Overweight and Obesity, Type 2 Diabetes Mellitus
- AZD9550Phase 23 trials
AstraZeneca · Overweight and Obesity, Obesity/Overweight, Obesity or Overweight
- TE-8105 MADPhase 22 trials
Immunwork, Inc. · Overweight and Obesity
- WVE-007Phase 21 trial
Wave Life Sciences USA, Inc. · Overweight and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.